logo
logo

Atavistik Bio Announces $60 Million Series A Financing To Advance Genetically-Validated Targets In Metabolic Diseases And Cancer

Aug 24, 2021•about 4 years ago

Amount Raised

$60 Million

Round Type

series a

Cambridge

Description

Atavistik Bio (“Atavistik”, “Company”), a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced today that the Company had completed a $60 million Series A financing round. The financing was led by The Column Group and joined by Lux Capital, and Nextech Invest, Ltd.

Company Information

Company

Atavistik Bio

Location

Cambridge, Maryland, United States

About

Atavistik Bio (Atavistik) is a pre-clinical stage biotechnology company pioneering the identification of allosteric small molecule-protein interactions that have the potential to lead to the discovery and future clinical development of first-in-class drug compounds within oncology and metabolic diseases. Atavistik was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Led by an experienced management team and advisors, plus a robust investment syndicate, Atavistik is positioned to deliver transformational science to ultimately improve patient care. Learn more at AtavistikBio.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech